Albert David Ltd (ALBERTDAVD) — shareholding pattern, promoter holding, financials and share price
About Albert David Ltd (ALBERTDAVD)
Albert David Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as ALBERTDAVD and on the BSE under scrip code 524075. Its ISIN is INE155C01010.
Incorporated in 1938, Albert David Ltd is in the business of manufacturing pharmaceutical products [1]
Albert David Limited (ADL) specializes in manufacturing and trading pharmaceutical formulations, infusion solutions, herbal dosage forms, and bulk drugs, both domestically and internationally.
The company is a significant player in the IV fluid manufacturing sector, with production capabilities in both glass and polyethylene containers.
Listed peers in Pharmaceuticals: Transchem Ltd, Aptus Pharma Ltd, Astal Laboratories Ltd, Valiant Laboratories Ltd, Medicamen Biotech Ltd, Medico Remedies Ltd.
Valuation & Returns
10 Jul 2026At ₹694.01 a share on 10 Jul 2026, Albert David Ltd (ALBERTDAVD) was valued at a price-to-earnings ratio of -265.95x against an industry P/E of 36.41x and a price-to-book of 1.01x on a book value of ₹687.7 per share as of Mar 2025. Solomo computes return on equity of -0.38% and return on capital employed of 0.78% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- -265.95x
- Industry P/E
- 36.41x
- P/B
- 1.01x
- EPS (TTM)
- ₹-2.61
- Book value / share
- ₹687.7
- ROE
- -0.38%
- ROCE
- 0.78%
- ROA
- -0.29%
- Debt / equity
- 0.03x
- Dividend yield
- 0.72%
- EBITDA margin
- 3.87%
- 52-week range
- ₹581.3 – ₹945.85
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Albert David Ltd (ALBERTDAVD) reported revenue of ₹333 crore, net profit of ₹-1 crore and earnings per share of ₹-2.61. That compares with revenue of ₹345 crore and net profit of ₹17 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹86 crore and net profit ₹-21 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 313 | 341 | 362 | 345 | 333 |
| Net profit (₹ cr) | 35 | 36 | 75 | 17 | -1 |
| EPS (₹) | 61.78 | 63.38 | 132.15 | 30.14 | -2.61 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 0.39% | 1.51% | 3.32% | -4.60% |
| Profit growth | -10.78% | -2.14% | -21.28% | -77.19% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 62.24% of Albert David Ltd (ALBERTDAVD) (unchanged from the previous quarter), foreign institutional investors (FII) hold 0.57% and domestic institutional investors (DII) hold 1.64%. Market capitalisation was ₹396 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: HUF 1.88%, GENERAL INSURANCE CORPORATION OF INDIA 1.61%, VIKABH SECURITIES PVT. LTD. 1%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 62.24% | - | 0.57% | 1.64% | 37.76% |
| Mar 2026 | 62.24% | - | 0.58% | 1.66% | 37.76% |
| Dec 2025 | 62.24% | - | 0.6% | 1.66% | 37.76% |
| Sep 2025 | 62.24% | - | 0.6% | 1.66% | 37.76% |
| Jun 2025 | 62.24% | - | 0.84% | 1.66% | 37.76% |
| Mar 2025 | 62.24% | - | 1.01% | 1.65% | 37.76% |
| Dec 2024 | 62.13% | - | 0.86% | 1.64% | 37.87% |
| Sep 2024 | 62.13% | - | 0.88% | 1.64% | 37.87% |